

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -02

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi,
Ahmedabad, Gujarat-380006

Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com,

Website: www.kashyaptele-medicines.com

Date: 27th October, 2021

To,
BSE Limited
Listing Department
Phiroz Jeejeebhoy Tower,
25th Floor, Dalal Street,
Mumbai-400001

Scrip Code – 531960

Sub.: Submission of Unaudited Financial Results and statement of assets and liabilities of the Company and Limited Review Report thereon as per regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Second quarter and half year ended 30th September, 2021

Dear Sir/Madam,

With reference to above, we are pleased to submit herewith, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Unaudited Financial Results and statement of assets and liabilities of the Company for the second quarter and half year ended 30th September, 2021, prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015 (IND-AS), as reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on 27th October, 2021.

Also please find enclosed herewith the Limited Review Report of the said Unaudited Financial Results of the Company for the second quarter and half year ended 30th September, 2021 as received from the Auditors of the Company.


Further, pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the said result will be duly published in the required newspaper in due course of time and will be uploaded on the website of the Company.

Kindly take the above disclosures on your record as compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are requested to take note of the same.

Thanking you.

Yours faithfully,
For, KASHYAP TELE-MEDICINES LIMITED


PARITOSH TRIVEDI
COMPANY SECRETARY



Encl: As above



SAREMAL & CO

Chartered Accountants

CA Saremal Shah (Bcom, FCA); CA Pravin Lavana (Bcom, LLB, FCA)

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE QUARTERLY UNAUDITED FINANCIAL RESULTS AND STATEMENT OF ASSETS AND LIABILITIES FOR THE SECOND QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2021 OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED


To
The Board of Directors,
KASHYAP TELE-MEDICINES LIMITED
AHMEDABAD

1. We have reviewed the accompanying statement of Un-audited Financial Results and Statement of Assets and Liabilities of M/S KASHYAP TELE-MEDICINES LIMITED (the Company) for the second quarter and half year ended 30th September, 2021 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended (the 'Listing Regulations'), read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, SEBI Circular No. CIR/CFD/CMD1/44/2019 dated 29th March, 2019 and SEBI Circular No. CIR/CFD/CMD1/80/2019 dated 19th July, 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Statement on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial Results and Statement of Assets and Liabilities are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results and statement of Assets and Liabilities prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our Conclusion is not modified in respect of this matter.

Place : Ahmedabad
Date: 27th October, 2021

FOR SAREMAL & CO.
CHARTERED ACCOUNTANTS



PRAVIN LAVANA
(PARTNER)
MEMBERSHIP NO.: 037180
FIRM REGISTRATION NO.: 109281W
UDIN No. 21037180AAAADL9865

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -02
 Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006
 Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com
 Website: www.kashyaptele-medicines.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2021
 (As per Schedule III Companies Act, 2013 and IND-AS)

(Rs in Lakhs Except EPS)

S.No.	Particulars	Quarter Ended (Standalone)			Half Year Ended		Year Ended
		30-09-2021	30-06-2021	30-09-2020	30-09-2021	30-09-2020	31-03-2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from operations	4.75	5.00	4.75	9.75	9.99	18.54
II	Other Income	0.00	0.00	0.00	0.00	0.00	0.14
III	Total Revenue (I + II)	4.75	5.00	4.75	9.75	9.99	18.68
IV	Expenses						
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(d) Employee benefits expense	2.22	2.21	2.53	4.43	3.94	8.65
	(e) Finance Cost	0.00	0.00	0.00	0.00	0.00	0.00
	(f) Depreciation and amortisation expense	0.00	0.00	0.00	0.00	0.00	0.00
	(g) Other expenses	1.97	1.89	2.13	3.86	4.25	8.54
	Total expenses	4.19	4.10	4.66	8.29	8.19	17.19
V	Profit before exceptional and extraordinary items and tax (III-IV)	0.56	0.90	0.09	1.46	1.80	1.49
VI	Exceptional and Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit Before Tax (V- VI)	0.56	0.90	0.09	1.46	1.80	1.49
VIII	Tax Expense :-						
	(a) Current Tax	0.12	0.21	0.02	0.33	0.41	0.39
	(b) Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
	Total Tax Expense	0.12	0.21	0.02	0.33	0.41	0.39
IX	Profit / (Loss) for the period from Continuing Operations (VII-VIII)	0.44	0.69	0.07	1.13	1.39	1.10
X	Profit/(Loss) from Discontinuing Operations	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax expense of Discontinuing Operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit/(Loss) from Discontinuing Operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Profit / (Loss) for the period (IX + XII)	0.44	0.69	0.07	1.13	1.39	1.10
XIV	Share of Profit / (Loss) of Associates	N.A	N.A	N.A	N.A	N.A	N.A
XV	Minority Interest	N.A	N.A	N.A	N.A	N.A	N.A
XVI	Profit / (Loss) after Taxes, minority interest and share of profit / (loss) of associates	0.44	0.69	0.07	1.13	1.39	1.10
XVII	Other Comprehensive Income						
	Item not reclassified through profit and loss:						
	(a) Fair value changes of the preference stock through OCI	0.00	0.00	0.00	0.00	0.00	0.00
XVIII	Total comprehensive income for the period (XVI+XVII)	0.44	0.69	0.07	1.13	1.39	1.10
XIX	Paid-up Equity Share Capital (Face Value of Rs. 1/- each)	477.22	477.22	477.22	477.22	477.22	477.22
XX	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	(237.79)
XXI	Earnings per equity Share: (not annualised)	0.001	0.001	0.000	0.002	0.003	0.002
	(a) Basic and Diluted EPS (XVI/XIX)						

Notes:

- 1 The above Unaudited Financial Results and Statement of Assets & Liabilities of the Company for the quarter and half year ended 30th September, 2021 have been reviewed by the Audit Committee and approved by the Board of Directors in the Meeting held on 27th October, 2021.
- 2 The Company has adopted, Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ('Ind As') from 1st April, 2017 and accordingly these financial results and all the periods presented have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting" read with relevant rules issued thereunder and the other accounting principles generally accepted in India and discloses the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 (as amended).
- 3 The Statutory Auditors of the Company have carried out an Audit of the above unaudited Financial Results and Statement of Assets & Liabilities for the quarter and half year ended on 30th September, 2021 in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and have expressed an unmodified audit opinion thereon .
- 4 Estimates of uncertainties relating to the global pandemic from COVID-19:
The Company has considered the possible effects that may result from the pandemic relating to COVID-19 on the carrying amounts of receivables ,revenues and intangible assets. In developing the assumptions relating to the possible future uncertainty in the global economic condition because of this pandemic, the Company as at the date of approval of these financial statement has used internal and external sources of informations, economic forecasts and consensus estimates from market sources on the expected future performance of the Company. The Company has performed sensitivity analysis on the estimates expects the carrying amount of these assets will be recovered.
- 5 Pursuant to compliance of SEBI notification No. SEBI/LAD-NRO/GN/2018/1 dated 9th May, 2018 , a Statement Of Cash Flows for the Half Year ended 30th September, 2021 has also been submitted by way of a note as enclosed herewith as Annexure-A.
- 6 A Copy of the aforesaid financial results is also available on the website of BSE Limited (www.bseindia.com) and on the website of the Company (www.kashyaptele-
- 7 The company is engaged in single segment therefore has only one reportable segment in accordance with Ind AS 108 'Operating Segments'.
- 8 Figures pertaining to previous year/periods have been re-grouped and re-arranged wherever necessary.

Place : Ahmedabad
 Date : 27th October, 2021



For, Kashyap Tele-Medicines Limited

(Signature)

Raghav Agrawal
 Director/Chief Financial Officer
 DIN: 02264149

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandañwadi, Mumbai –02

Corp. Off. : "Suryarath", 1st Floor, Panchwati, 1st Lane, Ambawadi, Ahmedabad – 380006

Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com

Website: www.kashyaptele-medicines.com

STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2021

(Rs. In Lakhs)

Particulars	As at 30-09-2021 (Unaudited)	As at 31-03-2021 (Audited)
I Non-Current Assets		
(a) Property, Plant and Equipment	-	-
(b) Capital work in progress	-	-
(c) Financial Assets	-	-
(i) Investments	21.00	21.00
(ii) Other Financial Assets	0.34	0.34
(d) Other Non-Current Assets	195.89	190.89
	217.23	212.23
II Current Assets		
(a) Inventories	-	-
(b) Financial Assets	-	-
(i) Trade Receivables	13.47	14.44
(ii) Cash and Cash Equivalents	8.20	13.45
(iii) Investments	-	-
(iv) Loans	-	-
(c) Other Current Assets	3.00	0.68
(d) Accrued Interest - FDR	-	-
	24.67	28.57
TOTAL ASSETS	241.90	240.80
I Equity		
(a) Share Capital	477.22	477.22
(b) Other Equity	(236.67)	(237.79)
	240.55	239.43
II Non Current Liabilities		
(a) Long term borrowings	-	-
(b) Deferred tax liabilities (net)	-	-
(c) Other long term liabilities	-	-
III Current Liabilities		
(a) Financial liabilities		
(i) Short term borrowings	-	-
(ii) Trade Payables	-	-
Total Outstanding dues of micro enterprises and small enterprises	-	-
Total Outstanding dues of creditors other than micro enterprises and small enterprises	-	0.29
(iii) Other Financial liabilities	0.68	0.74
(b) Other Current Liabilities	-	-
(c) Short-Term Provisions	-	-
(d) Income tax liabilities	0.67	0.34
	1.35	1.37
TOTAL EQUITY AND LIABILITIES	241.90	240.80


Place : Ahmedabad

Date : 27th October, 2021



For, Kashyap Tele - Medicines Limited




Raghav Agrawal
 Director/Chief Financial Officer
 DIN: 02264149

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -02

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006

Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com


Website: www.kashyaptele-medicines.com

STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2021


(As per Schedule III Companies Act, 2013 and IND-AS)

(Rs. In Lakhs)

Particulars	For the Year ended	
	30-09-2021	31-03-2021
A Cash flow from operating activities:		
Profit before tax	1.46	1.49
Adjustments		
Depreciation and amortisation expense	-	-
Interest expense	-	-
Interest income	-	-
Dividend income on current investments	-	-
Profit on sale of fixed assets	-	-
Profit on sale/fair market valuation of investment	-	-
Fair market valuation of derivatives	-	-
Unclaimed balances written back	-	-
Bad debts written off	-	-
Expected credit loss	-	-
Amortisation of government grant	-	-
Provision for doubtful advances	-	-
Diminution in value of current investments	-	-
Liability no longer required written back	-	-
Operating profit before working capital changes	1.46	1.49
Adjustments for changes in working capital :		
Change in trade receivables	0.96	(1.45)
Movement in other assets	0.00	0.00
Decrease/(Increase) in inventories	0.00	0.00
Decrease/ in current investments	0.00	0.00
(Increase) in financial assets	0.00	0.00
Change in other receivables	(7.32)	2.96
Change in Current Liabilities & other payables	(0.02)	0.07
Cash flow from/ (used in) operations	(4.92)	3.07
Income taxes paid	0.33	0.39
Net cash flow from/(used in) operating activities	(5.25)	2.68
B Cash flow from investing activities:		
Purchase of fixed assets (including capital work-in-progress, capital advances and intangibles under development)	-	-
Proceeds from sale of fixed assets	-	-
Purchase of investments	-	-
Proceeds from sale of investments	-	-
Net proceeds (to)/from loans and advances	-	-
Net proceeds (to)/from deposits	-	-
Dividend received	-	-
Interest received	-	-
Net cash (used in)/flow from investing activities	0.00	0.00
C Cash flow from financing activities:		
Net (repayment)/proceeds from short-term borrowings	-	-
Repayment of short-term borrowings	-	-
Repayment of short-term borrowings	-	-
Proceeds from long-term borrowings	-	-
Repayment of long-term borrowings	-	-
Interest paid	-	-
Net cash (used in)/flow from financing activities:	0.00	0.00
D Net increase in cash and cash equivalents	(5.25)	2.68
Cash and cash equivalents at the beginning of the year	13.45	10.77
Cash and cash equivalents at the end of the year	8.20	13.45

Place : Ahmedabad
Date : 27th October, 2021

For, Kashyap Tele - Medicines Limited

Raghav Agrawal
Director/Chief Financial Officer
DIN: 02264149